Skip to Content

Hyzaar FDA Alerts

The FDA Alert(s) below may be specifically about Hyzaar or relate to a group or class of drugs which include Hyzaar (hydrochlorothiazide/losartan).

MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.

Recent FDA Alert(s) for hydrochlorothiazide/losartan

FDA Updates on Angiotensin II Receptor Blocker (ARB) Recalls

Nov 13, 2019

Audience: Consumer, Health Professional, Pharmacy

Investigation ongoing – This page to be updated as more information is available

IMPORTANT: Medications containing only amlodipine or hydrochlorothiazide (HCTZ) are not being recalled. Manufacturers are recalling medications containing amlodipine in combination with valsartan or losartan, and medications containing hydrochlorothiazide HCTZ in combination with valsartan or losartan.


UPDATE - FDA warns Mylan for CGMP deviations

Update [11/13/2019] Today, the U.S. Food and Drug Administration posted a warning letter to Mylan Pharmaceuticals, Inc. in Chodavaram Village, Vizianagaram, Andhra Pradesh, India. Mylan manufactures valsartan active pharmaceutical ingredient (API) and has been one subject of an ongoing global investigation into nitrosamine impurities in angiotensin II receptor blockers (ARBs) such as valsartan, losartan and irbesartan.

The warning letter outlines several current good manufacturing practice (CGMP) deviations at this Mylan facility, including failure to have adequate written procedures for the receipt, identification and handling of raw materials and failure to adequately clean equipment and utensils. Failure to correct these deviations may result in further action by the agency. The warning letter is another result of the agency’s ongoing investigation.

FDA reminds patients taking recalled ARBs to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition.

UPDATE - FDA warns Torrent for CGMP violations

Update [10/15/2019] Today, the U.S. Food and Drug Administration posted a warning letter to Torrent Pharmaceuticals in Ahmedabad, Gujarat, India. Torrent manufactures losartan potassium tablets and has been one subject of an ongoing global investigation into nitrosamine impurities in angiotensin II receptor blockers (ARBs) such as valsartan, losartan and irbesartan.

The warning letter outlines several manufacturing violations at Torrent’s Taluka-Kadi, Indrad, Gujarat facility, including failure to follow written procedures for production and process control and failure to adequately investigate batch discrepancies. Failure to correct these violations may result in further action by the agency. The warning letter is another result of the agency’s ongoing investigation.

FDA reminds patients taking recalled ARBs to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition.

UPDATE - Torrent expands its voluntary recall of losartan

Update [9/20/2019] Torrent Pharmaceuticals is expanding its voluntary recall to include five additional lots of losartan potassium tablets (three lots of losartan potassium tablets and two lots of losartan potassium/hydrochlorothiazide (HCTZ) combination tablets). This recall is due to unacceptable amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in the losartan active pharmaceutical ingredient manufactured by Hetero Labs Limited. Torrent is recalling lots of losartan-containing medication that tested positive for NMBA above 9.82 parts per million.

The agency updated the list of recalled angiotensin II receptor blockers (ARBs) accordingly.

FDA reminds patients taking recalled ARBs to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition.

UPDATE - Statement on the agency’s ongoing efforts to resolve safety issue with ARB medications

Update [8/28/19]  Protecting patients is the FDA’s highest priority, and Americans can be confident in the quality of the products the agency approves. The recent Angiotensin II Receptor Blocker (ARB) recalls have deeply concerned patients, the medical community, the agency and international regulatory bodies. The FDA is aware many patients rely on ARB medicines, and we are concerned about the presence of nitrosamine impurities in these drugs. Millions of people benefit from the high-quality products that the FDA regulates, and the U.S. has the most robust drug supply in the world, with strict standards for safety, effectiveness and quality.

Clarifying the risk and scope of exposure

As part of our efforts to be transparent regarding impurities in ARBs, we want to make sure patients have a full understanding of how these impurities may affect them. Notably, we would like to stress that the actual risk to patients is likely much lower than our estimates, which reflect a scientific assessment of the highest possible exposure. Weinitially estimated that if 8,000 people took the highest valsartan dose (320 mg) containing N-Nitrosodimethylamine (NDMA) from the recalled batches daily for four years, there may be one additional case of cancer over the lifetimes of those 8,000 people. In reality, the vast majority of patients exposed to NDMA through ARBs received much smaller amounts of the impurity than this worst-case scenario, and, since not all ARBs are affected, it’s very likely that a patient taking an ARB for four years would not have always received one of the affected products.

One question we have received from many patients and other stakeholders is how big the impact has been – how many patients have been affected? While we know the number of patients taking ARB medicines, we do not know the exact number of patients impacted by these ARB recalls. The reasons for this are nuanced. For example, we understand that health care professionals, out of an abundance of caution, may have replaced their patients’ ARB prescriptions that were not part of the announced recalls. Because patients’ prescription bottles do not always identify lot numbers, it was difficult for patients and pharmacists to determine whether a medicine was part of the recalls. Patients may have returned medication unnecessarily if their supply was not part of a recall, but they were unsure. Therefore, we estimate there were likely more drugs replaced due to recalls than necessary, which means more patients were impacted but not necessarily exposed to an impurity.

Manufacturers only estimate the number of products still in the distribution chain that are subject to recall, but not the number of impacted patients. However, through our ongoing track and trace efforts for prescription drugs in the supply chain, we’re working on ways to improve industry’s ability to track, detect and remove potentially dangerous drugs from the supply chain more rapidly and efficiently. ARB medications that contain impurities above the published interim acceptable limits continue to be recalled, with certain exceptions. However, it’s also important to underscore that there are ARB medicines that remain on the market and have been determined not to contain any nitrosamine impurities. We continue to encourage patients talk to a health care professional if they have questions about their medicine, as the risks of stopping taking an ARB product for treating high blood pressure and heart failure greatly outweighs the potential risk of exposure to trace amounts of nitrosamines.

Enhancing oversight of manufacturing data

As we continue our analysis of this situation to better understand the root causes, we’re learning more about how nitrosamine impurities may have formed and been present in ARBs. Through each step of our investigation, we’ve uncovered new information and taken a number of actions, including regulatory and advisory actions, where appropriate, to prevent the presence of unacceptable levels of these impurities. For example, earlier this month, we issued a warning letter to Lantech Pharmaceuticals Limited in Telangana, India, for current good manufacturing practice violations. Lantech acts as a contract solvent recovery facility for valsartan active pharmaceutical ingredient (API) manufacturing operations. When we inspected Lantech in March 2019, we determined that solvent recovered by the company contained N-Nitrosodiethylamine (NDEA) and that Lantech had insufficiently assessed the risks associated with their processes and did not adequately investigate the impurities. Specifically, the warning letter cites Lantech’s failure to control and monitor procedures to recover solvents to ensure that they meet appropriate standards before reuse. After we gathered and evaluated all the facts, we placed Lantech on import alert in June 2019, preventing API made using its recovered solvent from legally entering the U.S.

We continue to work closely with our global regulatory partners, including the European Medicines Agency (EMA), Health Canada, and many others, to understand the full scope of this issue. We share inspectional findings, laboratory testing methods and results, and our assessments of root cause and impact. We are working to incorporate what we have learned about the process risks that caused these impurities into our oversight of drug manufacturing, which includes how we assess applications and changes to applications, as well as enhancing our inspection coverage to evaluate the controls in place to prevent unacceptable levels of nitrosamine. For example, we plan to adjust inspections of API sites to include enhanced evaluation of impurity controls, particularly when the manufacturing process may lead to the formation of a nitrosamine or when recycled raw materials can create unacceptable contamination. In the past year, the agency has conducted multiple unannounced, for-cause inspections to evaluate the practices at various API manufacturers and to verify appropriate corrective actions to address the risk of nitrosamine contamination. We are also working to improve how companies submit manufacturing changes to the agency with the goal of further improving our review of the more than 5,000 quality-related application change requests (supplements) each year.

We continue to work with our global regulatory partners and industry as members of the International Conference on Harmonization (ICH) to publish guidance on controlling impurities in drugs and managing changes (e.g., ICHQ3A, Q3C, Q3D, Q7, Q11, and M7). These guidances and others developed through ICH are revised as new impurities and risks are identified and have helped prevent unacceptable impurities in drugs. We work with manufacturers during application review and after marketing begins over the lifecycle of their drugs to evaluate proposed process changes, conduct facility inspections, test samples of marketed drugs, evaluate complaints, and investigate issues that arise, all to protect the safety and quality of medicines.

Expanding our investigation

We have known that certain drug manufacturing processes pose a risk for forming genotoxic impurities, and this is an issue the FDA and other regulators have been working on for a number of years – well before the nitrosamine impurities were discovered in ARBs last summer. In fact, we issued guidance in early 2018 to provide information to manufacturers regarding their responsibilities to assess the risks and implement appropriate controls for their manufacturing process. Now that we know some of the root causes of the nitrosamine impurity problem, we’re using these findings to inform our evaluation of medicines other than ARBs. We are testing samples of other drugs with similar manufacturing processes. If we detect a problem, we will take appropriate action. In the meantime, we continue to work with ARB manufacturers to remove all affected drugs from the market, and we work with API manufactures to fix their processes so they do not distribute affected API to drug product manufacturers.

Our list of affected products and products without impurities remains available to the public, and we will update it when we have new information to share. We will also continue to provide timely updates about any future issues associated with this ongoing incident that may impact public health.

As we work to safeguard the quality of our medicines, the American public can expect that we will act quickly to address any issue as soon as we find out about it to prevent as much harm to patients as possible. We’re also committed to communicating as transparently as possible. When we found out about the impurities in ARB products, we worked with industry and our international regulatory colleagues to understand the situation and take preventative measures. We have also communicated frequently over the past year to share timely safety and manufacturing information. We have consistently and transparently communicated with pharmacists, patients and health care professionals about the ARB recalls as they have evolved.

Ultimately, our goal is to be certain that no ARBs with unacceptable impurity levels reach patients. Based on our current assessments, including lab testing, the agency has identified 43 ARB medications that have been determined not to contain any nitrosamine impurities. As we continue our assessments and as companies continue to manufacture ARBs without nitrosamine impurities to replenish the U.S. supply, we expect this figure to rise. We know that ARBs can be produced without nitrosamine impurities, and we are working with manufacturers to reach that point.

UPDATE - Macleods Pharmaceuticals voluntarily recalls losartan containing NMBA

Update [6/26/2019] FDA is alerting patients and health care professionals to Macleods Pharmaceuticals’ voluntary recall of two lots of losartan potassium tablets (50mg strength) and 30 lots of losartan potassium/hydrochlorothiazide (HCTZ) combination tablets (12 lots of 50mg/12.5mg strength, three lots of 100mg/12.5mg strength, and 15 lots of 100mg/25mg strength). This recall is due to unacceptable amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in the losartan active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.

FDA is working with manufacturers to reduce and remove nitrosamines from angiotensin II receptor blockers (ARBs). The agency also updated the list of recalled angiotensin II receptor blockers (ARBs) .

FDA reminds patients taking recalled ARBs to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition.

UPDATE - Teva expands its voluntary recall of losartan

Update [6/12/2019] Teva Pharmaceuticals is expanding its voluntary recall to include seven additional lots of losartan potassium tablets (three lots of 50 mg strength and four lots of 100 mg strength) labeled by Golden State Medical Supply. This recall is due to unacceptable amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in the losartan active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. Teva is recalling lots of losartan-containing medication that tested positive for NMBA above 9.82 parts per million.

The agency updated the list of recalled angiotensin II receptor blockers (ARBs) accordingly.

FDA reminds patients taking recalled ARBs to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition.

UPDATE - FDA alerts patients and health care professionals to Vivimed’s recall of losartan medication due to NMBA

Update [5/6/2019] FDA is alerting patients and health care professionals to a voluntary recall of 19 lots of losartan potassium tablets made by Vivimed Life Sciences Pvt Ltd in Alathur, Chennai, India and distributed by Heritage Pharmaceuticals Inc, East Brunswick, New Jersey, due to the detection of the impurity N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). Vivimed is recalling lots of losartan-containing medication that tested positive for NMBA above 9.82 parts per million.

Manufacturers should contact FDA’s Drug Shortages Staff when their testing of losartan shows levels of NMBA that exceed the interim acceptable intake limit of 0.96 ppm. FDA will determine, on a case-by-case basis, whether lots containing NMBA greater than 0.96 ppm should be released for distribution.

FDA reminds patients taking recalled angiotensin II receptor blockers (ARBs) to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition.

The agency also updated the list of recalled ARBs.

UPDATE - Laboratory analysis of valsartan products

Update [5/2/2019] FDA posted laboratory test results showing NDEA levels in recalled valsartan products as well as an assessment of the cancer risk from NDEA in valsartan.

FDA alerts patients and health care professionals to Teva’s recall and Legacy’s expanded recall of losartan medication due to NMBA

Update [4/29/2019] FDA is alerting patients and health care professionals to a voluntary recall of 44 lots of losartan potassium tablets manufactured by Teva Pharmaceuticals and labeled as Golden State Medical Supply due to the detection of the impurity N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). The recalled products were made with active pharmaceutical ingredient (API) manufactured by Hetero Labs. Teva is recalling lots of losartan-containing medication that tested positive for NMBA above 9.82 parts per million.

Additionally, Legacy expanded its recall to include one additional lot of losartan tablets made with API manufactured by Hetero Labs.

Manufacturers should contact FDA’s Drug Shortages Staff when their testing of losartan shows levels of NMBA that exceed the interim acceptable intake limit of 0.96 ppm. FDA will determine, on a case-by-case basis, whether lots containing NMBA greater than 0.96 ppm should be released for distribution.

The agency also updated the list of recalled losartan medicines.

Torrent further expands its voluntary recall of losartan; FDA posts new nitrosamine testing methods

Update [4/19/2019] Torrent Pharmaceuticals Limited is further expanding its voluntary recall to include 104 additional lots of losartan potassium and losartan potassium/hydrochlorothiazide combination tablets. This recall is due to unacceptable amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in the losartan active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.

FDA reminds patients taking recalled angiotensin II receptor blockers (ARBs) to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition.

FDA is also posting new testing methods which can help manufacturers and international regulators detect and identify multiple nitrosamine impurities. FDA and international regulators have identified N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA) and NMBA in ARBs.

  • A direct injection GC-MS method that is able to detect NDMA, NDEA, N-Nitrosodiisopropylamine (NDIPA), N-Nitrosoethylisopropylamine (NEIPA), and N-nitrosodibutylamine (NDBA)
  • A headspace GC-MS method that is able to detect NDMA, NDEA, NDIPA, and NEIPA

These methods should be validated by the user if the resulting data are used to support a required quality assessment of the API or drug product, or if the results are used in a regulatory submission.

FDA updates recalled valsartan-containing and losartan-containing medicine information

Update [3/22/2019] FDA has updated the list of valsartan medicines under recall to incorporate additional repackagers of Aurobindo’s valsartan-containing medicine.

FDA not objecting to losartan with NMBA below 9.82 ppm remaining on the market

Update [3/20/2019] To ensure patient access to losartan, FDA will not object to certain manufacturers temporarily distributing losartan containing N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) above the interim acceptable intake limit of 0.96 parts per million (ppm) and below 9.82 ppm until the impurity can be eliminated. The agency expects many companies will be able to manufacture losartan without nitrosamine impurities and replenish the U.S. supply in approximately six months.

Agency scientists evaluated the risk of exposure to NMBA at levels up to 9.82 ppm and determined that it presents no meaningful difference in cancer risk over a six-month time period when compared to a lifetime of exposure to NMBA at 0.96 ppm. Distributing losartan containing NMBA up to 9.82 ppm, will help maintain adequate losartan supply while companies obtain approval for manufacturing processes that produce nitrosamine-free losartan for patients.

FDA reminds patients taking recalled losartan to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition. Untreated hypertension (high blood pressure) leads to an increase in the risk of heart attacks and stroke. Untreated heart failure increases the risk of hospitalization and death. Untreated diabetic nephropathy (kidney disease) leads to worsening renal (kidney) disease.

Manufacturers should contact FDA’s Drug Shortages Staff when their testing of losartan shows levels of NMBA that exceed the interim acceptable intake limit of 0.96 ppm. FDA will determine, on a case-by-case basis, whether lots containing NMBA greater than 0.96 ppm should be released for distribution.

FDA continues to work with companies and international regulators to ensure products entering the U.S. market do not contain nitrosamine impurities.

Torrent again expands its voluntary recall of losartan; Hetero also voluntarily recalls losartan

Update [3/1/2019] Torrent Pharmaceuticals Limited is further expanding its voluntary recall to include 114 additional lots of losartan potassium and losartan potassium/hydrochlorothiazide combination tablets. This recall is due to unacceptable amounts of N-Methylnitrosobutyric acid (NMBA) in the losartan active pharmaceutical ingredient manufactured by Hetero Labs Limited.

Today, the agency also issued a press release to provide additional information about its ongoing investigation and another voluntary recall by Hetero/Camber Pharmaceuticals, which was announced on February 28, of 87 lots of losartan potassium tablets (25 mg, 50 mg and 100 mg). The recalled losartan potassium and losartan potassium/hydrochlorothiazide tablets are also manufactured by Hetero, which are distributed by Camber, and contain the impurity NMBA.

Torrent and Hetero/Camber are only recalling lots of losartan-containing medication with NMBA above the interim acceptable intake limits of 0.96 parts per million (ppm).

Aurobindo expands its voluntary recall of valsartan and amlodipine/valsartan

Update [3/1/2019] AurobindoPharma USA is expanding its voluntary recall to include 38 additional lots of valsartan and amlodipine/valsartan combination tablets. The recall is due to unacceptable amounts of N-Nitrosodiethylamine (NDEA) found in the medicine.

Aurobindo is only recalling lots of valsartan-containing medication where NDEA has been detected above the interim acceptable intake limit of 0.083 parts per million. FDA is working with manufacturers to reduce and remove nitrosamines from angiotensin II receptor blockers (ARBs).

The agency also updated the valsartan products under recall.

FDA updates table of interim limits for nitrosamine impurities in ARBs

Update [2/28/2019] FDA is posting the updated table of interim acceptable intake limits for nitrosamine impurities to reflect N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) limits, which are the same as those for NDMA.

The agency will use the interim limits below to recommend manufacturers conduct a voluntary recall if laboratory testing confirms the presence of nitrosamine impurities in finished drug product. FDA is working with industry and international regulators to ensure products entering the market do not contain these impurities, but we are tolerating the impurities below the level established in the table for a short period of time to avoid a possible shortage of ARBs.

Not all ARB products contain NDMA, NDEA or NMBA impurities, so pharmacists may be able to provide an alternative medication not affected by the recalls, or health care professionals may prescribe a different medication that treats the same condition.

Interim Limits for NDMA, NDEA, and NMBA in Angiotensin II Receptor Blockers (ARBs)

Drug Maximum Daily Dose (mg/day) Acceptable Intake NDMA (ng/day)*    Acceptable Intake NDMA (ppm)** Acceptable Intake NDEA (ng/day)*     Acceptable Intake NDEA (ppm)** Acceptable Intake NMBA (ng/day)*     Acceptable Intake NMBA (ppm)**
Valsartan 320 96 0.3 26.5 0.083 96 0.3
Losartan 100 96 0.96 26.5 0.27 96 0.96
Irbesartan 300 96 0.32 26.5 0.088 96 0.32
Azilsartan 80 96 1.2 26.5 0.33 96 1.2
Olmesartan 40 96 2.4 26.5 0.66 96 2.4
Eprosartan 800 96 0.12 26.5 0.033 96 0.12
Candesartan 32 96 3.0 26.5 0.83 96 3.0
Telmisartan 80 96 1.2 26.5 0.33 96 1.2

* The acceptable intake is a daily exposure to a compound such as NDMA, NDEA, or NMBA that approximates a 1:100,000 cancer risk after 70 years exposure
** These values are based on a drug's maximum daily dose as reflected in the drug label

Losartan distributed by Macleods Pharmaceuticals voluntarily recalled

Update [2/25/2019] FDA is alerting patients and health care professionals to a voluntary recall of one lot of losartan potassium/hydrochlorothiazide (HCTZ) 100mg/25mg combination tablets manufactured by Macleods Pharmaceuticals. The recall is due to unacceptable amounts of N-Nitrosodiethylamine (NDEA) found in the medicine made with active pharmaceutical ingredient manufactured by Hetero Labs Limited.

Macleods is only recalling lots of losartan-containing medication where NDEA has been detected above the interim acceptable intake limit of 0.27 parts per million. FDA is working with manufacturers to reduce and remove nitrosamines from angiotensin II receptor blockers (ARBs).

Torrent further expands its voluntary recall of losartan

Update [1/23/2019] Torrent Pharmaceuticals is further expanding its voluntary recall to include six additional lots of losartan potassium and hydrochlorothiazide combination tablets, for a total of 16 lots of losartan-containing medicines. This recall is due to unacceptable amounts of N-Nitrosodiethylamine (NDEA) in the losartan active pharmaceutical ingredient manufactured by Hetero Labs Limited.

Torrent is only recalling lots of losartan-containing medication containing NDEA above the interim acceptable intake limits of 0.27 parts per million (ppm).

Irbesartan distributed by Solco Healthcare voluntarily recalled

Update [1/18/2019] FDA is alerting patients and health care professionals to a voluntary recall of one lot of irbesartan and seven lots of irbesartan and hydrochlorothiazide (HCTZ) combination tablets distributed by Solco Healthcare LLC, a Prinston Pharmaceutical Inc. subsidiary. The recall is due to unacceptable amounts of N-Nitrosodiethylamine (NDEA) in the irbesartan active pharmaceutical ingredient manufactured by Zhejiang Huahai Pharmaceuticals (ZHP).

Solco is only recalling lots of irbesartan-containing medication where NDEA has been detected above the interim limit of 0.088 parts per million. FDA is working with manufacturers to reduce and remove nitrosamines from angiotensin receptor II blockers (ARBs).

The agency also updated the list of irbesartan products under recall.

Torrent expands its voluntary recall of losartan

Update [1/3/2019] Torrent Pharmaceuticals is expanding its voluntary recall to include eight additional lots of losartan potassium tablets, for a total of 10 lots. This recall is due to trace amounts of N-Nitrosodiethylamine (NDEA) in the losartan active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.

Torrent is only recalling lots of losartan medication containing NDEA above the interim acceptable intake level of 0.27 parts per million.

FDA alerts patients and health care professionals to Aurobindo’s recall of valsartan medication due to NDEA

Update [1/2/2019] FDA is alerting patients and health care professionals to Aurobindo Pharma USA’s voluntary recall of two lots of valsartan tablets, 26 lots of amlodipine and valsartan combination tablets, and 52 lots of valsartan and hydrochlorothiazide (HCTZ) combination tablets due to the amount of N-Nitrosodiethylamine (NDEA) in the valsartan active pharmaceutical ingredient. Aurobindo is recalling amlodipine and HCTZ only in combination medications containing valsartan. Neither amlodipine nor HCTZ is currently under recall by itself.

Aurobindo is recalling lots of valsartan-containing medication that tested positive for NDEA above the interim acceptable daily intake level of 0.083 parts per million.

The agency continues to investigate and test all angiotensin II receptor blockers (ARBs) for the presence of NDEA and N-Nitrosodimethylamine (NDMA) and is taking swift action when it identifies these impurities that are above interim acceptable daily intake levels.

FDA also updated the list of valsartan products under recall and the list of valsartan products not under recall.

FDA reminds patients taking any recalled ARB to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition. Some ARBs contain no NDMA or NDEA.

FDA alerts patients and health care professionals to Torrent’s recall of losartan medication due to NDEA

Update [12/20/2018] FDA is alerting patients and health care professionals to Torrent Pharmaceuticals’
voluntary recall of two lots of losartan potassium 100 mg tablets due to N-Nitrosodiethylamine (NDEA) in the losartan active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.

Not all Torrent losartan-containing medications distributed in the U.S. are being recalled. Torrent is recalling only those lots of losartan medication that tested positive for NDEA above the acceptable daily intake of 0.27 ppm.

The agency continues to investigate and test all angiotensin II receptor blockers (ARBs) for the presence of NDEA and N-Nitrosodimethylamine (NDMA) and is taking swift action when it identifies these impurities that are above acceptable daily intake levels.

FDA posted a list of losartan medications under recall. Additionally, FDA reminds patients taking this medication or any recalled ARB to continue taking their current medicine until their pharmacist provides a replacement or their doctor provides an alternative treatment option. It also is important to know not all ARBs contain NDMA or NDEA, so pharmacists may be able to provide a refill of medication not affected by the recall, or doctors may prescribe a different medication that treats the same condition.

FDA presents interim limits of nitrosamines in currently marketed ARBs

Update [12/19/2018] FDA is publishing interim acceptable intake levels of nitrosamine impurities in angiotensin II receptor blockers (ARBs) for manufacturers to use to ensure their finished drug products are safe for patients.

The agency evaluated safety data for N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) to determine an interim acceptable intake level for these impurities in the ARB class. NDMA and NDEA are probable human carcinogens and should not be present in drug products. We are currently aware of NDMA and NDEA in certain valsartan, irbesartan and losartan-containing products, and those products and some active pharmaceutical ingredients (API) used to manufacture them have been recalled from the U.S. market. See the list of valsartan products under recall and the list of irbesartan products under recall. 

Drug products that contain NDMA or NDEA above the limits in the table below pose an unacceptable risk to patients. The agency will use the interim limits to recommend manufacturers conduct a voluntary recall if laboratory testing confirms the presence of nitrosamine impurities in finished drug product. FDA is working with industry and international regulators to ensure products entering the market do not contain these impurities, but we are tolerating the impurities below the level established in the table for a short period of time to avoid a possible shortage of ARBs.

The agency reminds manufacturers they are responsible for developing and using suitable methods to detect impurities, including when they make changes to their manufacturing processes. If a manufacturer detects a new impurity or higher level of impurities, they should fully evaluate the impurities and take action to ensure the product is safe for patients. To aid industry and regulatory agencies, FDA has developed and published methods to detect NDMA and NDEA impurities – the gas chromatography/mass spectrometry (GC/MS) headspace method, the combined GC/MS headspace method, and the combined GC/MS direct injection method. These methods can be used for drug substances and products, and users should validate them as part of good manufacturing practices and where data are used to support a regulatory submission or required quality assessment of the API or drug product.

Not all ARB products contain NDMA or NDEA impurities, so pharmacists may be able to provide an alternative medication not affected by the recalls, or health care professionals may prescribe a different medication that treats the same condition.

Interim Limits for NDMA and NDEA in Angiotensin II Receptor Blockers (ARBs)

Drug Maximum Daily Dose (mg/day) Acceptable Intake NDMA (ng/day)*    Acceptable Intake NDMA (ppm)** Acceptable Intake NDEA (ng/day)*     Acceptable Intake NDEA (ppm)**
Valsartan 320 96 0.3 26.5 0.083
Losartan 100 96 0.96 26.5 0.27
Irbesartan 300 96 0.32 26.5 0.088
Azilsartan 80 96 1.2 26.5 0.33
Olmesartan 40 96 2.4 26.5 0.66
Eprosartan 800 96 0.12 26.5 0.033
Candesartan 32 96 3.0 26.5 0.83
Telmisartan 80 96 1.2 26.5 0.33

* The acceptable intake is a daily exposure to a compound such as NDMA or NDEA that results in a 1:100,000 cancer
risk after 70 years exposure
** These values are based on a drug's maximum daily dose as reflected in the drug label

For comparison with the levels of NDMA found in some common foods, please see our Aug. 20, 2018, update.

FDA updates NDMA and NDEA detection methods, announces posting of ZHP warning letter

Update [12/12/2018] The FDA has updated its testing methods to detect NDMA and NDEA impurities – the (GC/MS) headspace method, the combined headspace method, and the combined direct injection method – by adding the limits of detection (LOD) and clarifying that the methods can be used for both drug substances and drug products. These methods were validated with respect to valsartan drug substances and drug products, but the agency expects them to have comparable LODs and limits of quantitation (LOQ) for other angiotensin II receptor blockers (ARB).

Mylan expands its voluntary recall of valsartan-containing products

Update [12/6/2018] Mylan Pharmaceuticals is expanding its voluntary recall to include all lots of non-expired valsartan-containing products due to trace amounts of N-Nitrosodiethylamine (NDEA) in the valsartan active pharmaceutical ingredient (API) manufactured by Mylan Laboratories Limited. The 104 additional lots include 26 lots of amlodipine and valsartan tablets, 51 lots of valsartan tablets and 27 lots of valsartan and hydrochlorothiazide tablets. These lots were distributed in the U.S. between March 2017 and November 2018. 

The agency also updated the list of valsartan products under recall and the list of valsartan products not under recall.

FDA alerts patients and health care professionals to Teva’s recall of valsartan products due to NDEA

Update [11/27/2018] FDA is alerting patients and health care professionals to Teva Pharmaceuticals’ voluntary recall of valsartan-containing products manufactured using active pharmaceutical ingredient (API) from Mylan Pharmaceuticals. Mylan voluntarily recalled valsartan-containing products on November 20.

Teva is recalling all lots of amlodipine and valsartan combination tablets and amlodipine, valsartan, and hydrochlorothiazide (HCTZ) combination tablets due to the presence of N-Nitrosodiethylamine (NDEA). Teva has recalled other valsartan-containing products in recent months due to the presence of N-Nitrosodimethylamine (NDMA). With this recall, Teva has now recalled all their unexpired valsartan-containing products from the U.S. market.

The agency continues to investigate and test all angiotensin II receptor blocker (ARBs) for the presence of NDMA and NDEA and is taking swift action when it identifies these impurities that are above acceptable levels.

FDA has updated the list of valsartan products under recall and the list of valsartan products not under recall. The agency reminds patients taking this medication or any recalled ARB to continue taking their current medicine until their pharmacist provides a replacement or their doctor provides an alternative treatment option. It also is important to know that not all ARBs contain NDMA or NDEA, so pharmacists may be able to provide a refill of medication not affected by the recall, or doctors may prescribe a different medication that treats the same condition.

FDA alerts patients and health care professionals to Mylan’s recall of valsartan products due to NDEA

Update [11/21/2018] FDA is alerting patients and health care professionals to Mylan Pharmaceuticals’ voluntary recall of 15 lots of valsartan-containing products due to the presence of N-Nitrosodiethylamine (NDEA).

Not all Mylan valsartan-containing products distributed in the U.S. are being recalled. Mylan is recalling only those lots of valsartan-containing products that tested positive for NDEA above the acceptable level. The agency continues to investigate and test all angiotensin II receptor blockers (ARBs) for the presence of NDEA and N-Nitrosodimethylamine (NDMA) and is taking swift action when it identifies these impurities that are above acceptable levels.

FDA has updated lists of valsartan products under recall and valsartan products not under recall. Additionally, FDA reminds patients taking this medication or any recalled ARB to continue taking their current medicine until their pharmacist provides a replacement or their doctor provides an alternative treatment option. It also is important to know not all ARBs contain NDMA or NDEA, so pharmacists may be able to provide a refill of medication not affected by the recall, or doctors may prescribe a different medication that treats the same condition.

FDA has also posted questions and answers to assist health care professionals and patients.


FDA alerts patients and health care professionals to Sandoz’s losartan potassium and hydrochlorothiazide recall of one lot due to NDEA

Update [11/9/2018] FDA is alerting patients and health care professionals to Sandoz’s voluntary recall of one lot – JB8912 – of losartan potassium and hydrochlorothiazide 100mg/25mg tablets, that contain losartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a diuretic, used in combination for the treatment of hypertension. Sandoz’s product was made using an active pharmaceutical ingredient (API) that has tested positive for NDEA. The API was manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd, which is on import alert.

Sandoz’s losartan drug products make up less than 1 percent of the total losartan drug products in the U.S. market.

FDA continues to investigate the presence of NDEA and NDMA, which are probable human carcinogens, in ARBs and is taking swift action when it identifies unacceptable impurities in API and finished drug products.

FDA reminds patients taking this medication or any recalled ARB to continue taking their current medicine until their pharmacist provides a replacement or their doctor provides an alternative treatment option. It also is important to know not all ARBs contain NDEA or NDMA, so pharmacists may be able to provide a refill of medication not affected by the recall, or doctors may prescribe a different medication that treats the same condition.


FDA alerts patients and health care professionals to ScieGen’s irbesartan recall due to NDEA

Certain irbesartan products labeled as Westminster Pharmaceuticals Inc. and GSMS Inc. recalled

Update [10/30/2018] FDA is alerting patients and health care professionals to ScieGen’s voluntary recall of certain lots of irbesartan, an angiotensin II receptor blocker (ARB), because they contain N-Nitrosodiethylamine (NDEA), a known animal and suspected human carcinogen (causes cancer). FDA laboratory testing confirmed NDEA in some lots of ScieGen’s irbesartan. ScieGen’s irbesartan products are labeled as Westminster Pharmaceuticals and Golden State Medical Supply, Inc. (GSMS). See the list of irbesartan products under recall. This is the first non-valsartan drug product the agency has found to contain the NDEA impurity.

ScieGen’s recall affects about 1 percent of the irbesartan drug products in the U.S. market.

Additionally, Aurobindo, which manufactures the active pharmaceutical ingredient (API) for ScieGen’s irbesartan products, is recalling all unexpired lots of its irbesartan API supplied to the U.S. market with NDEA. FDA and Aurobindo laboratory testing confirmed NDEA in certain lots of their irbesartan API.

FDA reminds patients taking any recalled ARB to continue taking their current medicine until their pharmacist provides a replacement or their doctor provides an alternative treatment option. Not all ARBs contain NDEA or N-Nitrosodimethylamine (NDMA), a probable human carcinogen previously found in certain recalled valsartan products, so pharmacists may be able to provide a refill of medication not affected by the recall, or doctors may prescribe a different medication that treats the same condition.

To date, ScieGen is the only manufacturer of irbesartan drug products found to contain NDEA. FDA continues to test all ARBs for the presence of impurities and has publicly posted two methods for manufacturers and regulatory agencies around the world to test their ARBs for the unexpected NDMA and NDEA impurities. The combined headspace method and the combined direct injection method can detect and quantify NDMA and NDEA simultaneously in ARB API and finished drug products.

FDA continues to work with API and drug manufacturers to ensure their products are not at risk for NDMA or NDEA formation. The agency reminds manufacturers they are responsible for developing and using suitable methods to detect impurities, including when they make changes to their manufacturing processes. If a manufacturer detects new or higher levels of impurities, they should fully evaluate the impurities and take action to ensure the product is safe for patients.

For additional information about ARB products, see:

  • list of valsartan products under recall
  • list of valsartan products not under recall

FDA updates recalled valsartan-containing product information

Update [10/24/2018] FDA continues to evaluate valsartan-containing products and other angiotensin II receptor blockers (ARBs), and has updated the list of products included in the recall to add one additional lot of RemedyRepack.

FDA releases additional NDMA/NDEA detection method

Update [10/16/2018] FDA is posting a gas chromatography-tandem mass spectrometry (GC-MS/MS) method utilizing liquid injection for detecting the presence of impurities N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) in valsartan drug products.

This method provides an additional option for regulators and industry to detect NDMA and NDEA impurities. This method can be used alone or in combination with the combined gas chromatography-mass spectrometry (GC/MS) headspace method the agency recently posted. Like the previously posted methods, this method should be validated by the user if the resulting data are used to support a required quality assessment of the API or drug product, or if the results are used in a regulatory submission.

FDA releases method for detection and quantification of both NDMA and NDEA

Update [10/11/2018] ] FDA is posting a redeveloped combined gas chromatography-mass spectrometry (GC/MS) headspace method for detecting the presence of impurities N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) in valsartan drug products.

FDA previously posted a GC/MS method for detection of NDMA in valsartan products. Upon detection of NDEA in valsartan products manufactured by Zhejiang Huahai Pharmaceuticals, FDA redeveloped the testing method so that it can be used to detect and quantify levels of both NDMA and NDEA. This method should be validated by the user if the resulting data are used to support a required quality assessment of the API or drug product, or if the results are used in a regulatory submission.

FDA is also working on a GC/MS direct injection method for detection of NDMA and NDEA. We will post the method when it is available. This will provide an additional option for regulators and industry to use to detect both impurities.

FDA posts laboratory analysis of NDMA levels in recalled valsartan products

Update [10/5/2018] FDA posted laboratory test results showing NDMA levels in recalled valsartan products. FDA will also post test results and an assessment of the cancer risk from NDEA when they are available.

FDA places Zhejiang Huahai Pharmaceuticals on import alert

Update [9/28/2018] FDA placed Zhejiang Huahai Pharmaceuticals on import alert on September 28, 2018, to protect U.S. patients while the active pharmaceutical ingredient (API) manufacturer fully determines how impurities were introduced into its API and remediates its quality systems. The import alert stops all API made by ZHP and finished drug products made using ZHP’s API from legally entering the United States. FDA’s action follows a recent inspection at ZHP’s facility.

FDA reminds manufacturers that it is their responsibility to develop and use suitable methods to detect impurities, including when they make changes to their manufacturing processes. If a manufacturer detects new or higher levels of impurities, they should fully evaluate the impurities and take action to ensure the product is safe for patients.

FDA updates recall lists and releases method for the detection and quantification of NDMA in valsartan

Update [9/24/2018] FDA has updated the list of valsartan products not under recall with five Teva products that were not previously on either list.

Update [8/24/2018] Torrent Pharmaceuticals Limited is expanding its voluntary recall. FDA has updated the list of valsartan products under recall.

Update [8/22/2018] Torrent Pharmaceuticals Limited is expanding its voluntary recall to all lots of unexpired valsartan-containing drug products due to the detection of NDMA in the active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals.

RemedyRepack, a repackager of Torrent’s valsartan/amlodipine/hydrochlorothiazide (HCTZ) tablets, has also recalled.

FDA has updated the list of valsartan products under recall and the list of valsartan products not under recall.

Additionally, FDA is releasing a gas chromatography-mass spectrometry (GC/MS) headspace method for manufacturers and regulators to detect and quantify NDMA in valsartan API and finished drug products. The agency is using this method to test potential NDMA-containing APIs and drug products. This method should be validated by the user if the resulting data are used to support a required quality assessment of the API or drug product, or if the results are used in a regulatory submission.

FDA updates recalled valsartan-containing product information and presents NDMA levels in some foods

Update [8/20/2018] FDA is alerting health care professionals and patients that Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of valsartan/amlodipine/hydrochlorothiazide (HCTZ) tablets. Not all Torrent valsartan products distributed in the U.S. are being recalled.

FDA recently learned Torrent used affected valsartan active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. FDA testing confirmed NDMA in some Torrent products.

To date, Torrent has not received any reports of adverse events related to this recall.

FDA has updated the list of valsartan products under recall and the list of valsartan products not under recall to incorporate additional repackagers of Camber’s valsartan products and Torrent’s recall.

NDMA is a known environmental contaminant. For context, it is found in water and foods including meats, dairy products and vegetables.

Estimated Range of Daily NDMA Consumption for certain foods (Recommended daily food consumption rates based on Dietary Guidelines for Americans 2015-2020)

  • Cured meat - 0.004-0.23 micrograms1

  • Smoked meat - 0.004-1.02 micrograms1

  • Grilled meat - 0.006-0.13 micrograms1

  • Bacon - 0.07-0.09 micrograms2

    • In more ordinary terms, for example, one pound of bacon may contain 0.304-0.354 micrograms of NDMA

FDA reminds patients taking valsartan from a recalled lot that they should continue taking their current medicine until their doctor or pharmacist provides a replacement or a different treatment option. Not all valsartan products contain NDMA, so pharmacists may be able to provide a refill of valsartan medication not affected by the recall, or doctors may prescribe a different medication that treats the same condition.

__________________________________

1 Mavelle, T., B. Bouchikhi, and G. Debry, The occurrence of volatile N-nitrosamines in French foodstuffs. Food Chemistry, 1991. 42(3): p. 321-338.

2 Park, J., et al., Distribution of Seven N-Nitrosamines in Food. Toxicol Res, 2015. 31(3): p. 279-288.


FDA updates recalled valsartan-containing product information

Update [8/9/2018] FDA has updated the list of valsartan products under recall and the list of valsartan products not under recall to incorporate recalls of valsartan-containing products manufactured by Hetero Labs Limited, in India, labeled as Camber Pharmaceuticals Inc. Not all Camber valsartan products distributed in the U.S. are being recalled.

Camber Pharmaceuticals is recalling certain valsartan tablets because they contain the impurity N-nitrosodimethylamine (NDMA) in the active pharmaceutical ingredient (API). Hetero Labs manufactures the API for the Camber products using a process similar to Zhejiang Huahai Pharmaceuticals.

Test results from Hetero Labs show the amount of NDMA found in its valsartan API exceeds acceptable levels; although it is generally lower than the amount discovered in the API manufactured by Zhejiang.

FDA is testing samples of valsartan API and finished products to confirm the extent and amount of NDMA and help inform the ongoing investigation. The agency has also contacted other manufacturers of valsartan API to determine if their manufacturing processes are at risk for the formation of NDMA, and is working with them to ensure NDMA is not present in future valsartan API.

Valsartan is an angiotensin II receptor blocker (ARB), and FDA is investigating whether other types of ARBs are at risk for the presence of NDMA.

Recalled valsartan products labeled as Camber may be repackaged by other companies. FDA will provide updates as more information becomes available.


FDA updates recalled valsartan-containing product information and reminds API manufacturers to evaluate processes for unsafe impurities

Update [8/2/2018] FDA continues to evaluate valsartan-containing products and has updated the list of products included in the recall and the list of products not included in the recall. In addition to updating the lists, FDA revised information related to A-S Medication on the list of products included in the recall. The agency will continue to provide information when it becomes available.

FDA is working with drug manufacturers to ensure future valsartan active pharmaceutical ingredients (APIs) are not at risk of NDMA formation. The agency reminds manufacturers to thoroughly evaluate their API manufacturing processes, and changes to those processes, to detect any unsafe impurities. If a manufacturer detects new or higher levels of impurity, they should take action to prevent changes to the product’s safety profile. 


FDA updates recalled valsartan-containing product information

Update [7/27/2018] FDA is updating health care professionals and patients after discovering that several additional companies that repackage drug products are also recalling valsartan-containing products.

FDA has product recall information from three additional repackagers of valsartan-containing products made by Teva Pharmaceuticals and Prinston Pharmaceuticals Inc. – labeled as A-S Medication Solutions LLC, AvKARE and RemedyRepack – and the agency has added them to the recalled products list. Two of these companies, A-S Medication and RemedyRepack, may also distribute valsartan products not affected by the recall. The agency is confirming this information and will provide an update once it is available.

The following additional repackagers are recalling or are expected to recall valsartan-containing products. FDA is working to gather product recall information from these companies and has removed them from the list of products that are not impacted by this recall:

  • Bryant Ranch Prepack Inc.
  • H. J. Harkins Company Inc. (this company was not originally included on either list)
  • Lake Erie Medical, doing business as Quality Care Products LLC
  • NuCare Pharmaceuticals Inc.
  • Northwind Pharmaceuticals
  • Proficient Rx

It is possible that not all valsartan-containing products repackaged by these companies are impacted by the recall. FDA continues to evaluate valsartan-containing products and will update the list of products included in the recall and the list of products not included in the recall as more information becomes available.

Back to Top


Analysis of N-nitrosodimethylamine (NDMA) Levels in Recalled Valsartan in the U.S.

Update [7/27/2018] On July 13th, FDA announced a recall of certain batches of valsartan tablets because of an impurity, a chemical known as N-nitrosodimethylamine (NDMA). Valsartan is a medication commonly used to treat high blood pressure and heart failure.

NDMA has been found to increase the occurrence of cancer in animal studies. These animal studies were done using amounts of NDMA much higher than the impurity levels in recalled valsartan batches. Based on these animal studies, the U.S. Environmental Protection Agency considers NDMA a probable human carcinogen—a chemical that can increase the risk of cancer in humans. NDMA is found in some water supplies and in some foods1. Consuming up to 96 nanograms NDMA/day is considered reasonably safe for human ingestion2. It is estimated that over the course of a person’s lifetime, consuming this amount of NDMA would result in less than one additional case of cancer for every 100,000 people. To put this in context, currently one out of every three people in the US will experience cancer in their lifetime.

The amounts of NDMA found in the recalled batches of valsartan exceeded these acceptable levels. The agency wanted to put some context around the actual potential risk posed to patients who used versions of valsartan that may have contained high levels of NDMA. Based on records from the manufacturer of the recalled valsartan, some levels of the impurity may have been in the valsartan-containing products for as long as four years. FDA scientists estimate that if 8,000 people took the highest valsartan dose (320 mg) from the recalled batches daily for the full four years, there may be one additional case of cancer over the lifetimes of these 8,000 people. This assessment led to FDA’s decision to have these batches recalled.

Patients taking valsartan from a recalled batch should continue taking their current medicine until their doctor or pharmacist provides a replacement or a different treatment option. It is important to know that not all valsartan products contained NDMA, so pharmacists may be able to provide a refill of valsartan medication from batches that that are not affected by the recall, or doctors may prescribe a different medication that treats the same indications.

FDA continues to evaluate the safety of valsartan-containing products and will update the list of products included in the recall and the list of products not included in the recall as more information becomes available. If you are taking a valsartan product, be sure to check to back as the lists may change.

_________________________________

1 From Toxnet: https://toxnet.nlm.nih.gov/

Average Daily Intake: WATER: (assume 3 to 6 ng N-nitrosodimethylamine/l)(1) 6 to 12 ng; direct intake from drinking water is probably much less than 1 ug/day(2). FOOD: (assume <0.1 to 84 ug/kg)(4) <0.16 to 134 ug.
[(1) Kimoto WI et al; Water Res 15: 1099-1106 (1981) (2) USEPA; Ambient Water Quality Criteria Doc: Nitrosamines p.C-14 (1980) EPA 440/5-80-064 (4) IARC; IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 17: 125-76 (1978)]

2 The calculated acceptable intake for NDMA is based on methods described in the ICH Guidance M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk


FDA publishes a list of valsartan-containing products not part of the recall

Update [7/24/2018] FDA is updating health care professionals and consumers on the agency’s progress in responding to the ongoing recalls of valsartan, which is used to treat high blood pressure and heart failure, due to the presence of NDMA. The agency has posted a list of valsartan-containing products not impacted by this recall. FDA continues to evaluate valsartan-containing products and will update the list of products included in the recall and the list of products not included in the recall as more information becomes available.

Manufacturers of these products often produce multiple dosage strengths, however not all of them are being recalled. FDA recommends health care professionals and patients carefully check these lists. Health care professionals and patients should check this statement frequently for any updates.

FDA reminds consumers to continue taking your current medicine until your doctor or pharmacist gives you a replacement or a different treatment option. Untreated hypertension (high blood pressure) leads to an increase in the risk of heart attacks and stroke. Untreated heart failure increases the risk of hospitalization and death.

Consumers and health care professionals should continue to report any adverse reactions with valsartan-containing products, to the FDA’s MedWatch program to help the agency better understand the scope of the problem:


FDA updates health care professionals and patients on recent valsartan recalls

[7/18/2018] The U.S. Food and Drug Administration is updating health care professionals and consumers following a recent FDA press release about voluntary recalls of several drug products containing the active pharmaceutical ingredient (API) valsartan. Valsartan is used to treat high blood pressure and heart failure. Not all products containing valsartan are being recalled, and this update will clarify which valsartan-containing products are being recalled.

The recalled products contain an impurity, N-nitrosodimethylamine (NDMA), in the API manufactured by Zhejiang Huahai Pharmaceuticals, Linhai, China. The presence of the potentially cancer-causing NDMA was unexpected, and the agency believes the NDMA is related to changes in the way the active substance was manufactured. Some levels of the impurity may have been in the valsartan-containing products for as long as four years.

The investigation into valsartan-containing products is ongoing, and the following list may change. We will update this statement as we have more information.

There are currently three voluntary recalls related to the NDMA impurity detected in the valsartan API:

  • Teva Pharmaceuticals USA labeled as Major Pharmaceuticals — recall is at the retail level because these products are only used in facilities where they are directly administered to patients by health care professionals: Valsartan 80 mg and 160 mg products;
  • Prinston Pharmaceuticals Inc. labeled as Solco Healthcare LLC — recall is at the consumer/user level: Valsartan 40 mg, 80 mg, 160 mg, and 320 mg; and valsartan/HCTZ 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg products; and 
  • Teva Pharmaceuticals labeled as Actavis LLC — recall is at the consumer/user level: Valsartan 40 mg, 80 mg, 160 mg, and 320 mg; and valsartan/HCTZ 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg products.

What should patients know:

  • Continue taking your current medicine until your doctor or pharmacist gives you a replacement or a different treatment option.
  • Not all valsartan-containing medications are affected and being recalled.
  • If you are taking any medication containing valsartan, compare the information on your prescription bottle with the information in the list (company, National Drug Code, lot number) to determine if your current medicine has been recalled. If you are not certain, contact your pharmacist.
  • If you have medicine included in the recall, contact your pharmacist. The pharmacist may be able to provide you with valsartan made by another company. If not, contact your doctor immediately to discuss other treatment options.

What health care professionals should know:

  • FDA has determined the recalled valsartan products pose an unnecessary risk to patients. Therefore, FDA recommends patients use valsartan-containing medicines made by other companies or consider other available treatment options for the patient’s medical condition.
  • If you have medication samples from these companies, quarantine the products and do not provide them to patients.

Consumers and health care professionals should report any adverse reactions with valsartan-containing products, to the FDA’s MedWatch program to help the agency better understand the scope of the problem:

  • Complete and submit the report online at www.fda.gov
  • Download and complete the appropriate form, then submit it via fax at 1-800-FDA-0178

Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP

Sep 19, 2019

Audience: Consumer, Health Professional, Pharmacy

September 19, 2019 -- Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium / hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity while testing the below finished product batches manufactured utilizing active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited using the old Route of Synthesis. The recall is expanded to include an additional 3 lots of Losartan Potassium Tablets USP and 2 lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP.

The impurity detected is N-Methylnitrosobutyric acid (NMBA). Torrent is only recalling lots of losartan-containing products that contain N-Methylnitrosobutyric acid (NMBA) above the acceptable daily intake levels released by the FDA.

Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients. Losartan Potassium and Hydrochlorothiazide tablets, USP is used to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy.

Patients who are taking Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.

The product/lots included in the expanded recall are listed below. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.

Losartan Potassium Tablet and Losartan Potassium / Hydrochlorothiazide Tablet Lots

NDC Product Name, Strength and Package Count Batch Number Expiration Date
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E009 12/31/2020
13668-115-90 Losartan Potassium Tablets, USP 100mg, 90 count 4DU3E009 12/31/2020
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3D018 02/28/2021
13668-116-90 Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D051 11/30/2020
13668-118-90 Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count. 4P04D007 07/31/2020

Losartan Potassium tablets, USP and Losartan Potassium / Hydrochlorothiazide tablets, USP were distributed nationwide to Torrent's wholesale distributor, repackager and retail customers. Torrent Pharmaceuticals Limited is notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts. Torrent is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.

Consumers with medical questions regarding this recall or to report an adverse event can contact Torrent Pharmaceuticals Limited at:

  • 1-800-912-9561 (live calls received 8:00 am – 5:00 pm Eastern Time, voicemail available 24 hours/day, 7 days/week).
  • Medinfo.Torrent@apcerls.com

Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Any general questions regarding the return of this product should be directed to Qualanex at 1-888-280-2040 (live calls received 8 am - 9:00 pm Eastern Time).

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online: www.fda.gov/medwatch/report.htm
Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm
Call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Source: FDA

Macleods Pharmaceutical Limited Issues Voluntary Nationwide Consumer Level Recall of Losartan Potassium 50mg and Losartan Potassium/Hydrochlorothiazide combination Tablets 50mg/12.5mg, 100mg/12.5mg and 100mg/25mg due to detection of NMBA Impurity

Jun 26, 2019

Audience: Consumer, Health Professional, Pharmacy

June 26, 2019 -- Macleods Pharmaceuticals Limited has initiated a voluntary recall in the United States, to the patient level, of 32 lots of Losartan Potassium USP Tablets (2 lots of 50mg strength) and Losartan Potassium/Hydrochlorothiazide combination Tablets (12 lots of 50mg/12.5mg strength, 3 lots of 100mg/12.5mg strength and 15 100mg/25mg strength) to the patient level due to the detection of trace amounts of an unexpected impurity, N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). The impurity was found in 32 lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited that is above the US Food & Drug Administration's interim acceptable exposure limit of 9.82 ppm. Based on the available information, the risk of developing cancer in a few patients following long-term use of the product cannot be ruled out.

Losartan Potassium Tablets and Losartan Potassium/Hydrochlorothiazide combination Tablets are indicated to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy. Patients who are on Losartan Potassium Tablets and Losartan Potassium/Hydrochlorothiazide combination Tablets, USP should continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

To date, Macleods Pharmaceuticals Limited has not received any reports of adverse events related to this recall.

The products subject to recall are listed below and packaged in bottles. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.

Losartan Potassium Tablets 50 mg
NDC Manufacturer Product Description Lot/Batch Expiration Date
33342-045-10 Macleods Pharmaceuticals Limited Losartan Potassium.Tablets USP 50mg 90ct BLl711A Nov-19
33342-045-44 Macleods Pharmaceuticals Limited Losartan Potassium Tablets USP 50mg 1000ct BLl710A Nov-19
Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg
NDC Manufacturer Product Description Lot/Batch Expiration Date
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK719A Sep-19
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK720A Sep-19
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK721A Sep-19
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK722A Sep-19
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK723A Sep-19
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK724A Sep-19
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK725A Oct-19
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK726A Oct-19
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK804A Jan-20
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK806A Jan-20
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK825A Oct-21
33342-050-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg BLK826A Oct-21
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 12.5 mg
NDC Manufacturer Product Description Lot/Batch Expiration Date
33342-051-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 12.5 mg BLL801A Dec-19
33342-051-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 12.5 mg BLL802A Dec-19
33342-051-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 12.5 mg BLL803A Dec-19
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg
NDC Manufacturer Product Description Lot/Batch Expiration Date
33342-052-10 Macleods
Pharmaceuticals Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM716A Jul-19
33342-052-10 Macleods
Pharmaceuticals Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM717A Jul-19
33342-052-10 Macleods
Pharmaceuticals Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM719A Aug-19
33342-052-10 Macleods
Pharmaceuticals Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM720A Aug-19
33342-052-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM721A Sep-19
33342-052-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM722A Sep-19
33342-052-10 Macleods
Pharmaceuticals Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM723A Oct-19
33342-052-10 Macleods
Pharmaceutica Is Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM724A Oct-19
33342-052-10 Macleods Pharmaceutical Limited Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM725A Oct-19
33342-052-10 Macleods Pharmaceuticals
Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM726A Nov-19
33342-052-10 Macleods
Pharmaceuticals Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg I 25 mg BLM802A Dec-19
33342-052-10 Macleods Pharmaceutical Limited Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM803A Dec-19
33342-052-10 Macleods Pharmaceuticals
Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM825A Sep-21
33342-052-10 Macleods Pharmaceuticals
Limited
Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM826A Sep-21
33342-052-10 Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/ 25 mg BLM827A Sep-21

Losartan Potassium Tablets 50mg and Losartan Potassium/Hydrochlorothiazide combination Tablets 50mg/12.5mg, 100mg/25mg and 100mg/12.5mg were distributed nationwide to Macleods wholesale distributor and retail customers. Macleods Pharmaceuticals Limited is notifying its distributors and customers by phone and/or in writing to immediately discontinue distribution of the specific lot being recalled and to notify their sub-accounts. Macleods is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.

Consumers with medical questions regarding this recall or to report an adverse event can contact Macleods Pharmaceuticals Limited at 855-926-3384 (8:00 am - 5:00 pm EST).

If you have any general questions regarding the return of this product, please contact Qualanex at call 888-280-2046 (7:00 am to 4:00 pm CST Monday to Friday).

Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Source: FDA

Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP

Apr 18, 2019

Audience: Consumer, Health Professional, Pharmacy

April 18, 2019 -- Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.

The Recall is expanded to include an additional 36 lots of Losartan potassium Tablets USP and 68 lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP

The impurity detected in the API is N-Methylnitrosobutyric acid (NMBA). Torrent is only recalling lots of losartan-containing products that contain N-Methylnitrosobutyric acid (NMBA) above the acceptable daily intake levels released by the FDA.

To date, Torrent Pharmaceuticals Limited has not received any reports of adverse events related to this recall.

Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients. Losartan potassium and hydrochlorothiazide tablets, USP is used to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy.

Patients who are taking Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.

The product/lots included in the expanded recall are listed below in the second table. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.

Losartan Potassium Tablet and Losartan Potassium/ Hydrochlorothiazide Tablet Lots

NDC Finished Product Strength and Package Count Batch Number Expiration Date
13668-113-90 Losartan Potassium Tablets, USP 25mg, 90 count 4DU1E005 1/31/2021
13668-113-90 Losartan Potassium Tablets, USP 25mg, 90 count 4DU1E006 1/31/2021
13668-113-90 Losartan Potassium Tablets, USP 25mg, 90 count 4DU1E008 1/31/2021
13668-113-10 Losartan Potassium Tablets, USP 25mg, 1000 count 4DU1E007 1/31/2021
13668-409-30 Losartan Potassium Tablets, USP 50mg, 30 count 4DU2D077 10/31/2020
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2D087 10/31/2020
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2E023 1/31/2021
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2E024 1/31/2021
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2E026 1/31/2021
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2E027 1/31/2021
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2E028 1/31/2021
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2E029 1/31/2021
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2E020 1/31/2021
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4O50E007 8/31/2021
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4O50E008 8/31/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D067 9/30/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D069 9/30/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D063 9/30/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D064 9/30/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D065 9/30/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D066 9/30/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D084 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D085 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D083 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D082 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D072 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D077 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D078 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D079 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D081 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D080 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D070 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D073 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D074 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D075 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D086 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D088 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D089 10/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E019 1/31/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E021 1/31/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E022 1/31/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E025 1/31/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E032 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E033 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E034 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E035 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E036 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E037 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E038 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E039 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E041 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E103 6/30/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E101 6/30/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E102 6/30/2021
13668-115-90 Losartan Potassium Tablets, USP 100mg, 90 count 4DU3E014 1/31/2021
13668-115-90 Losartan Potassium Tablets, USP 100mg, 90 count 4DU3E015 1/31/2021
13668-115-90 Losartan Potassium Tablets, USP 100mg, 90 count 4DU3E065 7/31/2021
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3D018 11/30/2020
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3E062 6/30/2021
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3E063 6/30/2021
13668-116-30 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 30 count BEF7D017 6/30/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D010 4/30/2020
13668-116-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D011 4/30/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D018 6/30/2020
13668-116-90 Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D009 4/30/2020
13668-116-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count 4P02E002 1/31/2021
13668-116-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count 4P02E003 1/31/2021
13668-116-90 Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count 4P02E004 1/31/2021
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7D008 4/30/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7D022 8/31/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7D012 4/30/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7D013 4/30/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7D049 11/30/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count 4P02E005 1/31/2021
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count 4P02E006 1/31/2021
13668-117-30 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 30 count BEF8D058 11/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D023 4/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D024 4/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D025 4/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D009 3/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D010 3/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D011 3/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D012 3/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D013 3/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D054 10/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D055 10/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D056 10/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D057 11/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D007 3/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D008 3/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D020 4/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D021 4/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D022 4/30/2020
13668-118-30 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 30 count BEF6D038 4/30/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D030 4/30/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D031 4/30/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D047 7/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90count BEF6D048 7/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D049 7/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D050 7/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D051 7/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D082 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D083 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D084 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D085 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D086 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D087 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count 4P04E003 1/31/2021
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count 4P04E004 1/31/2021
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count 4P04E005 1/31/2021
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count 4P04E006 1/31/2021
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count 4P04E007 1/31/2021
13668-118-10 Losartan Potassium/Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count 4P04E008 1/31/2021
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count 4P04E009 1/31/2021
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D051 7/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D082 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D083 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D084 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D085 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D086 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D087 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count 4P04E003 1/31/2021
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count 4P04E004 1/31/2021
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count 4P04E005 1/31/2021
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count 4P04E006 1/31/2021
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count 4P04E007 1/31/2021
13668-118-10 Losartan Potassium/Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count 4P04E008 1/31/2021
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count 4P04E009 1/31/2021

PRODUCT/LOTS INCLUDED IN THE EXPANDED RECALL.

NDC Finished Product Strength and Package Count Batch Number Expiration Date
13668-113-90 Losartan Potassium Tablets, USP 25mg, 90 count BDK1C003 7/31/2019
13668-113-10 Losartan Potassium Tablets, USP 25mg, 1000 count BDK1C002 7/31/2019
13668-113-10 Losartan Potassium Tablets, USP 25mg, 1000 count 4DU1D004 12/31/2019
13668-113-10 Losartan Potassium Tablets, USP 25mg, 1000 count 4DU1D005 12/31/2019
13668-113-10 Losartan Potassium Tablets, USP 25mg, 1000 count 4DU1D006 12/31/2019
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2D005 12/31/2019
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2D006 12/31/2019
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2D026 3/31/2020
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2D027 3/31/2020
13668-409-90 Losartan Potassium Tablets, USP 50mg, 90 count 4DU2D029 3/31/2020
13668-409-90 Losartan Potassium Tablets, USP 50mg,90 count 4DU2E007 12/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D040 8/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D041 8/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D042 8/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D017 2/29/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D025 3/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D028 3/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D045 8/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D046 8/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D047 8/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2D048 8/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E042 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count 4DU2E044 2/28/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count BDK2E001 12/31/2020
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count BDK2E012 8/31/2021
13668-409-10 Losartan Potassium Tablets, USP 50mg, 1000 count BDK2E013 8/31/2021
13668-115-90 Losartan Potassium Tablets, USP 100mg, 90 count 4DU3E016 1/31/2021
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3E017 1/31/2021
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3E019 2/28/2021
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3C012 7/31/2019
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3C015 8/31/2019
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3C016 8/31/2019
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3C017 8/31/2019
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3C031 9/30/2019
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3D007 1/31/2020
13668-115-10 Losartan Potassium Tablets, USP 100mg, 1000 count 4DU3D008 1/31/2020
13668-116-30 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 30 count BP02D005 12/31/2019
13668-116-30 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 30 count BP02C051 10/31/2019
13668-116-30 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 30 count BEF7D047 11/30/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BP02D006 12/31/2019
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BP02D007 12/31/2019
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BP02D012 1/31/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D003 3/31/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BP02C050 10/31/2019
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D026 8/31/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D027 8/31/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D028 8/31/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D045 11/30/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7D046 11/30/2020
13668-116-90 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count BEF7E005 1/31/2021
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7D005 3/31/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7D029 8/31/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7D030 8/31/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7D048 11/30/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7E001 12/31/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7E002 12/31/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7E003 12/31/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BEF7E004 12/31/2020
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BP02C051 10/31/2019
13668-116-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count BP02C052 10/31/2019
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D060 11/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D061 11/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D062 11/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D063 11/30/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BX35D024 1/31/2020
13668-117-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 count BEF8D064 11/30/2020
13668-117-10 Losartan Potassium /Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 1000 count BEF8D059 11/30/2020
13668-117-10 Losartan Potassium /Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 1000 count BEF8E004 1/31/2021
13668-117-10 Losartan Potassium /Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 1000 count BEF8E005 1/31/2021
13668-118-30 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 30 count BEF6D054 8/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D100 11/30/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D101 11/30/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D102 11/30/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6E001 12/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6E002 12/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6E003 12/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6E004 12/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6E008 12/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6E009 12/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6E010 12/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6E011 12/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6E012 12/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BP04D012 12/31/2019
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BP04D013 12/31/2019
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BP04C092 10/31/2019
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D012 3/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D013 3/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D060 9/30/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D061 9/30/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D063 9/30/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D076 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D077 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D078 10/31/2020
13668-118-90 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count BEF6D079 10/31/2020
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BP04C094 10/31/2019
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BEF6D096 11/30/2020
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BEF6D097 11/30/2020
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BEF6D098 11/30/2020
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BEF6D099 11/30/2020
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BEF6E005 12/31/2020
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BEF6E006 12/31/2020
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BP04D016 2/29/2020
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BP04D017 2/29/2020
13668-118-10 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count BP04D018 2/29/2020

Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.

Losartan potassium tablets, USP and Losartan potassium/ hydrochlorothiazide tablets, USP were distributed nationwide to Torrent’s wholesale distributor, repackager and retail customers. Torrent Pharmaceuticals Limited is notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts. Torrent is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.

Consumers with medical questions regarding this recall or to report an adverse event can contact Torrent Pharmaceuticals Limited at:

  • 1-800-912-9561 (live calls received 8:00 am – 5:00 pm Eastern Time, voicemail available 24 hours/day, 7 days/week).

  • Medinfo.Torrent@apcerls.com

Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Any general questions regarding the return of this product should be directed to Qualanex at 1- 888-280-2040 (live calls received 8 am - 9:00 pm Eastern Time).

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium /Hydrochlorothiazide Tablets, USP

Mar 1, 2019

Audience: Consumer, Health Professional, Pharmacy

Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Losartan potassium tablets USP and 54 lots of Losartan potassium/ hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.

The impurity detected in the API is N-Methylnitrosobutyric acid (NMBA). Torrent is only recalling lots of losartan-containing products that contain N-Methylnitrosobutyric acid (NMBA) above the acceptable daily intake levels released by the FDA.

To date, Torrent Pharmaceuticals Limited has not received any reports of adverse events related to this recall.

Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients. Losartan potassium and hydrochlorothiazide tablets, USP is used to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy.

Patients who are taking Losartan Potassium Tablets, USP and Losartan Potassium/ Hydrochlorothiazide Tablets, USP should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.

The products subject to recall are listed below. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.

Losartan Potassium Tablet and Losartan Potassium/ Hydrochlorothiazide Tablet Lots

NDCFinished Product Strength and Package CountBatch NumberExpiration Date
13668-113-90Losartan Potassium Tablets, USP 25mg, 90 count4DU1E0051/31/2021
13668-113-90Losartan Potassium Tablets, USP 25mg, 90 count4DU1E0061/31/2021
13668-113-90Losartan Potassium Tablets, USP 25mg, 90 count4DU1E0081/31/2021
13668-113-10Losartan Potassium Tablets, USP 25mg, 1000 count4DU1E0071/31/2021
13668-409-30Losartan Potassium Tablets, USP 50mg, 30 count4DU2D07710/31/2020
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4DU2D08710/31/2020
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4DU2E0231/31/2021
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4DU2E0241/31/2021
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4DU2E0261/31/2021
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4DU2E0271/31/2021
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4DU2E0281/31/2021
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4DU2E0291/31/2021
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4DU2E0201/31/2021
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4O50E0078/31/2021
13668-409-90Losartan Potassium Tablets, USP 50mg, 90 count4O50E0088/31/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D0679/30/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D0699/30/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D0639/30/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D0649/30/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D0659/30/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D0669/30/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D08410/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D08510/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D08310/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D08210/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D07210/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D07710/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D07810/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D07910/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D08110/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D08010/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D07010/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D07310/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D07410/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D07510/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D08610/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D08810/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2D08910/31/2020
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0191/31/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0211/31/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0221/31/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0251/31/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0322/28/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0332/28/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0342/28/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0352/28/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0362/28/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0372/28/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0382/28/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0392/28/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E0412/28/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E1036/30/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E1016/30/2021
13668-409-10Losartan Potassium Tablets, USP 50mg, 1000 count4DU2E1026/30/2021
13668-115-90Losartan Potassium Tablets, USP 100mg, 90 count4DU3E0141/31/2021
13668-115-90Losartan Potassium Tablets, USP 100mg, 90 count4DU3E0151/31/2021
13668-115-90Losartan Potassium Tablets, USP 100mg, 90 count4DU3E0657/31/2021
13668-115-10Losartan Potassium Tablets, USP 100mg, 1000 count4DU3D01811/30/2020
13668-115-10Losartan Potassium Tablets, USP 100mg, 1000 count4DU3E0626/30/2021
13668-115-10Losartan Potassium Tablets, USP 100mg, 1000 count4DU3E0636/30/2021
13668-116-30Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 30 countBEF7D0176/30/2020
13668-116-90Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 countBEF7D0104/30/2020
13668-116-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 countBEF7D0114/30/2020
13668-116-90Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 countBEF7D0186/30/2020
13668-116-90Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 countBEF7D0094/30/2020
13668-116-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count4P02E0021/31/2021
13668-116-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count4P02E0031/31/2021
13668-116-90Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count4P02E0041/31/2021
13668-116-10Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 countBEF7D0084/30/2020
13668-116-10Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 countBEF7D0228/31/2020
13668-116-10Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 countBEF7D0124/30/2020
13668-116-10Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 countBEF7D0134/30/2020
13668-116-10Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 countBEF7D04911/30/2020
13668-116-10Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count4P02E0051/31/2021
13668-116-10Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 1000 count4P02E0061/31/2021
13668-117-30Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 30 countBEF8D05811/30/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0234/30/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0244/30/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0254/30/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0093/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0103/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0113/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0123/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0133/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D05410/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D05510/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D05610/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D05711/30/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0073/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0083/31/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0204/30/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0214/30/2020
13668-117-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/12.5mg, 90 countBEF8D0224/30/2020
13668-118-30Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 30 countBEF6D0384/30/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D0304/30/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D0314/30/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D0477/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90countBEF6D0487/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D0497/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D0507/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D0517/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D08210/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D08310/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D08410/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D08510/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D08610/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 countBEF6D08710/31/2020
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count4P04E0031/31/2021
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count4P04E0041/31/2021
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count4P04E0051/31/2021
13668-118-90Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count4P04E0061/31/2021
13668-118-10Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count4P04E0071/31/2021
13668-118-10Losartan Potassium/Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count4P04E0081/31/2021
13668-118-10Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 1000 count4P04E0091/31/2021

Losartan potassium tablets, USP and Losartan potassium/ hydrochlorothiazide tablets, USP were distributed nationwide to Torrent’s wholesale distributor, repackager and retail customers. Torrent Pharmaceuticals Limited is notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts. Torrent is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.

Consumers with medical questions regarding this recall or to report an adverse event can contact Torrent Pharmaceuticals Limited at:

  • 1-800-912-9561 (live calls received 8:00 am – 5:00 pm Eastern Time, voicemail available 24 hours/day, 7 days/week).

  • Medinfo.Torrent@apcerls.com

Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Any general questions regarding the return of this product should be directed to Qualanex at 1- 888-280-2040 (live calls received 8 am - 9:00 pm Eastern Time).

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online: www.accessdata.fda.gov/scripts/medwatch/index.cfm

Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm

Call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA Impurity

Feb 22, 2019

Audience: Consumer, Health Professional, Pharmacy

Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg to the consumer level due to the detection of trace amounts of an unexpected impurity (NDEA) found in finished product manufactured with active pharmaceutical ingredient made by Hetero Labs Limited.

Risk Statement: The impurity detected is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. Macleods is recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg that contains NDEA above the interim acceptable daily intake levels released by the FDA.

To date, Macleods Pharmaceuticals Limited has not received any reports of adverse events related to this recall.

Losartan Potassium/Hydrochlorothiazide combination tablets are indicated to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy. Patients who are on Losartan Potassium/Hydrochlorothiazide combination tablets, USP should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

The product subject to recall is listed below and packaged in bottles. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.

NDC Manufacturer Product Description Lot/Batch Expiration Date
33342-0052-10 Macleods Pharmaceuticals Limited Losartan Potassium/ Hydrochlorothiazide combination tablets 100mg/25mg, 90 count bottles BLM715A Jul -2019

Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg were distributed nationwide to Macleods wholesale distributor and retail customers. Macleods Pharmaceuticals Limited is notifying its distributors and customers by phone and/or in writing to immediately discontinue distribution of the specific lot being recalled and to notify their sub-accounts. Macleods is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.

If you have any general questions regarding the return of this product please contact Qualanex via email at recall@qualanex.com or call 888-280-2042 (7:00 am to 4:00 pm CST Monday to Friday).

Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems associated with the use of this product may be reported to FDA's MedWatch Adverse Event Reporting program by phone, on line, either by regular mail or by fax.

  1. Complete and submit the report Online: www.accessdata.fda.gov/scripts/medwatch/index.cfm
  2. Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP

Jan 22, 2019

Audience: Consumer, Health Professional, Pharmacy.

Torrent Pharmaceuticals Limited is expanding its voluntary recall from 10 lots of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.

The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per international Agency for Research on Cancer (IARC) classification. Torrent is only recalling lots of losartan containing products that contain Nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.

To date, Torrent Pharmaceuticals Limited has not received any reports of adverse events related to this recall.

Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients. Patients who are on Losartan should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.

Patients who are on losartan potassium and hydrocholothiazide tablets, USP should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

The products subject to recall are listed below and packaged in bottles. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.

NDCManufacturerProduct DescriptionLot/BatchExpiration Date
13668-
115-30
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 100mg, 30count bottlesBO31C01604/2019
13668-
115-90
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 100mg, 90count bottlesBO31C01604/2019
13668-
115-10
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 100mg, 1000-count bottles4DK3C00504/2019
13668-
115-10
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 100mg, 1000-count bottles4DK3C00404/2019
13668-
115-10
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 100mg, 1000-count bottles4DU3C04010/2019
13668-
115-10
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 100mg, 1000-count bottles4DU3E04905/2021
13668-
115-10
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 100mg, 1000-count bottles4DU3E05005/2021
13668-
409-30
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 50mg, 30count bottles4L67C03510/2019
13668-
409-90
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 50mg, 90count bottles4L67C03510/2019
13668-
409-90
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 50mg, 90count bottles4L67C03610/2019
13668-
409-10
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 50mg, 1000-count bottles4O50C00511/2019
13668-
113-90
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM TAB, USP 25mg, 90count bottles4O49C01309/2019
13668-
116-90
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 50mg/12.5 mg, 90 count bottles.BP02C00803/2019
13668-
116-10
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 50mg/12.5 mg, 1000 count bottles.BEF7D00603/2020
13668-
117-90
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 100 mg/12.5 mg, 90 count bottles.BX35C02005/2019
13668-
117-90
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 100 mg/12.5 mg, 90 count bottles.BX35C04908/2019
13668-
117-10
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 100 mg/12.5 mg, 1000 count bottles.BX35C02205/2019
13668-
117-10
Torrent
Pharmaceuticals LTD
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 100 mg/12.5 mg, 1000 count bottles.BX35C02305/2019

Losartan potassium tablets, USP were distributed nationwide to Torrent’s wholesale distributor, repackager and retail customers. Torrent Pharmaceuticals Limited is notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts. Torrent is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.

Consumers with medical questions regarding this recall or to report an adverse event can contact Torrent Pharmaceuticals Limited at:

  • 1-800-912-9561 (live calls received 8:00 am – 5:00 pm Eastern Time, voicemail available 24 hours/day, 7 days/week).

Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Any general questions regarding the return of this product should be directed to Qualanex at 1-888-280-2040 (live calls received 8 am - 9:00 pm Eastern Time).

Adverse reactions or quality problems associated with the use of this product may be reported to FDA's MedWatch Adverse Event Reporting program either by phone, on line, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Link to Original Recall

Link to Expanded Recall

 

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Nov 8, 2018

Audience: Consumer, Health Professional, Pharmacy

November 8, 2018 -- Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC).

To date, Sandoz Inc. has not received any reports of adverse events related to this lot.

Losartan Potassium Hydrochlorothiazide Tablets, USP are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. The product can be identified as Losartan Potassium Hydrochlorothiazide, 100 mg/25 mg tablets in 1000-count plastic bottles, NDC 0781-5207-10, Lot number JB8912; Exp. Date 06/2020. This product was distributed nationwide to distributors. The affected product was not distributed prior to October 8, 2018.

Sandoz Inc. is notifying its distributors by letter via overnight mail and patients by this public notification. Distributors and retailers that have product which is being recalled should immediately stop distribution of the identified lot above and quarantine any quantities remaining in your control and return the recalled product to the identified Reverse Distributor.

Patients with questions regarding this recall can contact Sandoz Inc. at 1-800-525-8747 Monday-Friday 8:30 AM – 5:00 PM (EST) or email usdrugsafety.operations@novartis.com. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on Losartan Potassium Hydrochlorothiazide should continue taking their medication, as the risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using Losartan Potassium Hydrochlorothiazide.

Adverse reactions or quality problems associated with the use of this product may be reported to FDA's MedWatch Adverse Event Reporting program either by phone, on line, by regular mail or by fax.

This recall is being made with the knowledge of the Food and Drug Administration.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached more than 500 million patients. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.

Source: FDA

Angiotensin Receptor Blockers (ARBs): Drug Safety Communication - Drug Safety Review Completed

Jun 2, 2011

Audience: Cardiology, Oncology, Family Practice

[UPDATED 06/02/2011] FDA’s meta-analysis of 31 randomized controlled trials comparing ARBs to other treatment found no evidence of an increased risk of incident (new) cancer, cancer-related death, breast cancer, lung cancer, or prostate cancer in patients receiving ARBs.

 

[Posted 07/15/2010]

ISSUE: A recently published study - a meta-analysis combining cancer-related findings from several clinical trials - suggested use of ARBs may be associated with a small increased risk of cancer.

BACKGROUND: ARBs are used in patients with high blood pressure and other conditions. Brand names include Atacand, Avapro, Benicar, Cozaar, Diovan, Micardis, and Teveten.

The meta-analysis included data from over 60,000 patients in several long-term, randomized, controlled clinical trials evaluating ARBs for which adverse events related to cancer were captured during the study. The mean duration of follow-up ranged from 1.7 to 4.8 years.

The study reported the frequencies of new cancer occurrence to be 7.2% for patients receiving ARBs compared to 6.0% for those not receiving ARBs (risk ratio = 1.08, 95% Confidence Interval: 1.01-1.15). No statistically significant difference in cancer deaths was noted.

RECOMMENDATION: FDA has not concluded that ARBs increase the risk of cancer. The Agency is reviewing information related to this safety concern and will update the public when additional information is available. FDA believes the benefits of ARBs continue to outweigh their potential risks.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:


[06/02/2011 - Drug Safety Communication - FDA]
[07/15/2010 - Drug Safety Communication - FDA]

More Hyzaar Resources